NCT06655324View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions
Healthy
Interventions
BIOLOGICAL

V350A

Vaccination administered via intramuscular injection

BIOLOGICAL

V350B

Vaccination administered via intramuscular injection

BIOLOGICAL

Placebo

Vaccination administered via intramuscular injection

Trial Locations (9)

33143

ACTIVE_NOT_RECRUITING

QPS-MRA, LLC ( Site 0012), Miami

37909

RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0009), Knoxville

43215

RECRUITING

Remington-Davis, Inc. ( Site 0017), Columbus

64114

RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0008), Kansas City

65802

RECRUITING

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016), Springfield

68134

RECRUITING

Velocity Clinical Research, Omaha ( Site 0005), Omaha

68510

RECRUITING

Velocity Clinical Research Lincoln ( Site 0004), Lincoln

73112

RECRUITING

Lynn Health Science Institute ( Site 0010), Oklahoma City

91206

COMPLETED

California Clinical Trials Medical Group managed by PAREXEL ( Site 0011), Glendale

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY